Sirkka-Liisa Kivelä

Sirkka-Liisa Kivelä

Auto-generated profile, based on publicly available information

Sirkka-Liisa Kivelä

Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, Clinical Pharmacy Group, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2012 in Dementia and Geriatric Cognitive Disorders Extra
Verified
Journal Article
Open access
PDF file
JPJuha Puustinen
Juha Puustinen
JNJanne Nurminen
Janne Nurminen
TVTero Vahlberg
Tero Vahlberg
ALAlan Lyles
Alan Lyles
RIRaimo Isoaho
Raimo Isoaho
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
Background/Aims: Psychotropics and antiepileptics (AE) are medications commonly used among the aged with cognitive decline or dementia, although they may precipitate further cognitive decline. Our aim was to analyze the relationships between the use of (i) psychotropics (i.e. benzodiazepines or related drugs, BZD, antipsychotics, AP, or antidepressants, AD), opioids (Op), anticholinergics (ACh) or AEs or the concomitant use of two of these drugs, and (ii) the risk of precipitous cognitive decline in an older (≧65 years) cognitively disabled population. Methods: A longitudinal population-based study of general aged community-dwelling patients was executed in two phases (1990–1991 and 1998–1999) in Lieto, Finland. Fifty-two individuals cognitively disabled (MMSE score 0–23) at the 1990–1991 baseline form this study’s sample. Cognitive abilities were assessed in each phase with the Mini-Mental State Examination (MMSE) and medication utilization data were collected in both phases. The mean follow-up time was 7.6 years. Multivariate models were used to analyze the change in MMSE total score between medication users and non-users. Results: BZD or any psychotropic use was associated with greater cognitive decline in elders aged ≧75 years compared to non-users (change in MMSE sum score: –8.6 ± 7.0 vs. –3.3 ± 5.6 and –5.9 ± 7.0 vs. –2.7 ± 6.4, respectively). A greater decline was also associated specifically with the concomitant use of BZD and AP (–16 vs. –1.4 ± 7.8); as were BZD and any drug with CNS effects (–9.6 ± 9.9 vs. –1.3 ± 7.2) compared to non-users. The concomitant use of BZD and AD (–10.7 ± 4.7 vs. –3.2 ± 5.6) or ACh (–15.0 ± 8.5 vs. –3.3 ± 5.6) or any drug with CNS effects (–13.3 ± 6.5 vs. –3.3 ± 5.6) was associated with cognitive decline in patients ≧75 years compared to non-users of any drug with CNS effects. Conclusion: The use of a BZD or any psychotropic medication may be an independent risk factor for cognitive decline in the cognitively disabled aged, and patients co-prescribed psychotropic medications had greater cognitive decline. Studies with larger sample sizes and studies on possible pathophysiologic mechanisms are needed.

1 March 1996 in Age and Ageing
Verified
Journal Article
Open access
PDF file
SVSirkku Vilkman
Sirkku Vilkman
TKTimo Keistinen
Timo Keistinen
TTTuili Tuuponen
Tuili Tuuponen
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
A discharge register maintained by the National Research and Development Centre for Welfare and Health was employed to study the use of hospital services, attributable to chronic obstructive pulmonary disease (COPD), in Finland. From a total population of 5 million COPD caused 113016 hospital treatment periods during 1983–92 of persons aged 35 years or over. In men the need of hospital treatment for COPD started to rise sharply after the age of 50. Men aged 73 had the highest amount of admissions (3962 admissions per 10-year period). Women aged 68 had the highest amount of admissions (802 admissions per 10-year period). The highest admission rate per 1000 inhabitants was found for men at the age of 82 (37.0 admissions per 1000 population/year) and for women at the age of 77 (3.8 admissions per 1000 population/year). During the 10-year period a total of 27008 new COPD patients aged 35 or over received hospital care. The highest number of new admissions occurred among both sexes at the age of 71 (750 admissions per 10-year period in men and 233 admissions per 10-year period in women). This means that most of admissions are due to elderly COPD patients seeking treatment repeatedly. As the populations in the developed countries are ageing, the significance of COPD for the health care system is growing.

1 January 2002 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
MHM. Herala
M. Herala
SKS.-L. Kivelä
S.-L. Kivelä
RHR. Honkanen
R. Honkanen
KKK. Koski
K. Koski
PLP. Laippala
P. Laippala
HLH. Luukinen
H. Luukinen

1 October 2006 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
MSMarika Salminen
Marika Salminen
TLTerh Lehtimäki
Terh Lehtimäki
YFYue-Mei Fan
Yue-Mei Fan
TVTero Vahlberg
Tero Vahlberg
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
Objective: To compare serum lipids and their changes during a family-based health education in children aged 6–17 years with or without the ɛ4 allele of the gene encoding apolipoprotein E (apoE).Design: An intervention study.Setting: A family-based prevention of risk factors of coronary heart disease in Eastern Finland. The programme consisted of two counselling meetings at children's schools and three at children's homes.Subjects: Four hundred and thirty-nine children with a family history of cardiovascular diseases (CVD) participated in a family-based health education. The children were divided into two groups according toapoEgenotype. The risk group consisted of 143 children havingapoEɛ4 allele (genotype ɛ3/4 or ɛ4/4) and the non-risk group of 296 children withoutapoEɛ4 allele (ɛ2/3 or ɛ3/3). The final sample of the follow-up study included 354 (81%) children (114 and 240, respectively).Results: Baseline differences were found in low-density lipoprotein cholesterol (LDL-C) (P= 0.007) and LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio (P= 0.030) among boys and in total cholesterol (TC)/HDL-C (P= 0.008) and LDL-C/HDL-C ratios (P= 0.006) among girls. Differences between groups in changes during the follow-up were observed only for TC/HDL-C ratio (P-value adjusted for age = 0.049) among boys.Conclusions: At baseline, children withapoEɛ4 allele had on average a more unfavourable lipid profile than those withoutapoEɛ4 allele. However, the effect of about 33 months' family-based health education on plasma lipids did not depend onapoEgenotype in children with a family history of CVD.

30 November 2023 in Annals of Medicine
Verified
Journal Article
Open access
MDMaarit Dimitrow
Maarit Dimitrow
RSRoosa Saarenmaa
Roosa Saarenmaa
MAMarja Airaksinen
Marja Airaksinen
GHGhada Hassan
Ghada Hassan
EPEmmi Puumalainen
Emmi Puumalainen
TTTerhi Toivo
Terhi Toivo
Patient safety strategies highlight patients' own active involvement in ensuring medication safety. A prerequisite for involving patients in their medication therapy is having tools that can assist them in ensuring safe medicine use. Older home-dwelling adults with multiple medications are at high risk for medication-related problems, yet only a few age-specific patient self-administered medication risk screening tools exist. This study aimed to develop, validate, and assess the feasibility of a self-administered medication risk checklist for home-dwelling older adults ≥65 years. The draft checklist was formed based on a validated practical nurse-administered Drug Related Problem Risk Assessment Tool supplemented with findings from two systematic literature reviews. The content validity of the draft checklist was determined by a three-round Delphi survey with a panel of 19 experts in geriatric care and pharmacotherapy. An agreement of ≥80% was required. A feasibility assessment (i.e. understandability of the items, fill-out time of the checklist) of the content-validated checklist was conducted among older adults ≥65 years (n = 87) visiting community pharmacies (n = 4). Data were analysed using qualitative content analysis. The final validated and feasibility-tested Medication Risk Checklist (LOTTA) for home-dwelling older adults consists of eight items screening the highest priority systemic risks (three items), potentially drug-induced symptoms (one item), adherence, and self-management problems (four items). The checklist proved feasible for self-administration, the mean fill-out time being 6.1 min. A wide range of potential medication risks related to the medication use process can be identified by patient self-assessment. Screening tools such as LOTTA can enhance early detection of potential medication risks and risk communication between older adults and their healthcare providers. A wider and more integrated use of the checklist could be facilitated by making it electronically available as part of the patient information systems.

1 February 2006 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
SESeija I. Eskelinen
Seija I. Eskelinen
RIRaimo E. Isoaho
Raimo E. Isoaho
SKSirkka-Liisa Kivelä
Sirkka-Liisa Kivelä
KIKerttu M. Irjala
Kerttu M. Irjala